Preliminary study on the detection of endothelial cells in malignant ascites and its clinical significance
10.3781/j.issn.1000-7431.2015.33.638
- Author:
Xing YUAN
1
Author Information
1. Department of Medical Oncology, Anhui Provincial Hospital, Anhui Medical University
- Publication Type:Journal Article
- Keywords:
Endothelial cells;
Malignant ascites;
Recombinant human vascular endostatin
- From:
Tumor
2015;35(2):176-182
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To observe the clinical efficacy of intraperitoneal injection of recombinant human vascular endostatin combined with 5-fluorouracil (5-FU) in patients with malignant ascites, and to detect the change of percentage of endothelial cells (ECs) in ascites before and after treatment, in order to explore the clinical value of endothelial cells in treatment of malignant ascites. Methods: Thirty-nine patients with malignant ascites received two cycles of intraperitoneal inject of endostar combined with 5-FU treatment. The clinical response, change of quality of life (QOL) and the adverse events were assessed. The flow cytometry was used to detect the level of endothelial cells in malignant ascites before and after treatment. Results: In 39 patients, the objective response rate (complete response and partial response) was 43.6% (1 7/39); the rate of QOL improvement was 53.8% (21/39). The rates of grades 3-4 adverse events were low, including leukopenia in 2 patients (5.1%, 2/39), thrombocytopenia in 1 patient (2.6%, 1/39), anemia in 2 patients (5.1%, 2/39), nausea in 4 patients (10.3%, 4/39), and diarrhea in 1 patient (2.6%, 1/39). In 16 patients achieveing clinical response, the percentage of endothelial cells in malignant ascites before treatment was significantly higher than that after treatment [(0.22±0.06)% vs (0.12±0.08) %, P = 0.005]. In 21 patients achieveing improvement in QOL, the percentage of endothelial cells in malignant ascites before treatment was also significantly higher than that after treatment [(0.1 9±0.08)% vs (0.1 3±0.08) %, P = 0.032]. The percentages of endothelial cells in malignant ascites in patients not achieveing clinical response and improvement in QOL after treatment had no significant changes (P = 0.11 4, P = 0.359). Conclusion: Intraperitoneal inject of endostar combined with 5-FU treatment can effectively control the malignant ascites and improve the QOL. The level of endothelial cells in malignant ascites may become a clinical marker to predict the response to the treatment of malignant ascites.
